全文获取类型
收费全文 | 1658篇 |
免费 | 79篇 |
国内免费 | 148篇 |
专业分类
儿科学 | 64篇 |
妇产科学 | 6篇 |
基础医学 | 92篇 |
口腔科学 | 18篇 |
临床医学 | 202篇 |
内科学 | 277篇 |
皮肤病学 | 30篇 |
神经病学 | 19篇 |
特种医学 | 308篇 |
外科学 | 37篇 |
综合类 | 24篇 |
预防医学 | 48篇 |
眼科学 | 13篇 |
药学 | 441篇 |
1篇 | |
中国医学 | 1篇 |
肿瘤学 | 304篇 |
出版年
2023年 | 2篇 |
2022年 | 3篇 |
2021年 | 6篇 |
2020年 | 7篇 |
2019年 | 10篇 |
2018年 | 16篇 |
2017年 | 13篇 |
2016年 | 24篇 |
2015年 | 26篇 |
2014年 | 27篇 |
2013年 | 56篇 |
2012年 | 43篇 |
2011年 | 53篇 |
2010年 | 45篇 |
2009年 | 64篇 |
2008年 | 48篇 |
2007年 | 139篇 |
2006年 | 64篇 |
2005年 | 78篇 |
2004年 | 36篇 |
2003年 | 29篇 |
2002年 | 71篇 |
2001年 | 67篇 |
2000年 | 52篇 |
1999年 | 61篇 |
1998年 | 86篇 |
1997年 | 92篇 |
1996年 | 83篇 |
1995年 | 74篇 |
1994年 | 61篇 |
1993年 | 65篇 |
1992年 | 16篇 |
1991年 | 23篇 |
1990年 | 18篇 |
1989年 | 51篇 |
1988年 | 35篇 |
1987年 | 31篇 |
1986年 | 30篇 |
1985年 | 26篇 |
1984年 | 20篇 |
1983年 | 12篇 |
1982年 | 27篇 |
1981年 | 14篇 |
1980年 | 14篇 |
1979年 | 6篇 |
1978年 | 4篇 |
1977年 | 16篇 |
1976年 | 28篇 |
1975年 | 13篇 |
排序方式: 共有1885条查询结果,搜索用时 31 毫秒
61.
目的:观察白藜芦醇对一次性力竭游泳大鼠肝脏组织的作用及发挥作用的最佳口服剂量。方法:实验于2006-05/07在成都体育学院运动医学系动物实验室完成。①实验分组:选取雄性SD大鼠70只,随机分为7组,每组10只,分别为安静对照组,运动对照组,运动 15mg/kg白藜芦醇组,运动 50mg/kg白藜芦醇组,运动 100mg/kg白藜芦醇组,运动 200mg/kg白藜芦醇组,运动 300mg/kg白藜芦醇组。②实验干预:不同剂量白藜芦醇组每天灌胃15,50,100,200,300mg/kg白藜芦醇,安静对照组和运动对照组分别灌胃相同体积的溶媒(二甲亚砜 生理盐水),连续5周。末次给予实验用样品1h后,各运动组每只鼠尾跟部负荷3%体质量铅皮,置于水深50cm、水温(31±1)℃游泳槽中游泳。游泳力竭后即刻,股动脉取血并迅速取出肝组织。③指标检测:赖氏比色法测定血清中谷丙转氨酶活性;邻苯三酚自氧化法测定肝组织超氧化物歧化酶活性;硫代巴比妥酸法测定肝组织丙二醛含量。结果:纳入动物70只,均进入结果分析。①血清谷丙转氨酶活性和肝组织中丙二醛含量:运动对照组显著高于安静对照组,不同剂量白藜芦醇组低于运动对照组(P<0.05或P<0.01)。运动 100,200,300mg/kg白藜芦醇组低于运动 15,50mg/kg白藜芦醇组[谷丙转氨酶活性:(972.36±121.86),(944.36±105.35),(888.34±88.68),(1773.52±89.35),(1377.78±27.01)nkat/L,P<0.01;丙二醛含量:(7.90±2.56),(7.69±3.69),(7.13±2.62),(19.90±2.21),(12.16±1.78)μmol/g,P<0.05]。100,200,300mg/kg白藜芦醇组间差异无显著性。②肝脏组织中超氧化物歧化酶活性:运动对照组显著低于安静对照组,不同剂量白藜芦醇组高于运动对照组(P<0.05或P<0.01)。运动 100,200,300mg/kg白藜芦醇组高于15,50mg/kg白藜芦醇组[(2325.80±163.37),(2379.14±121.86),(2447.16±89.18),(1096.05±120.19),(1514.64±28.17)μkat/g,P<0.01]。结论:①白藜芦醇对力竭性运动大鼠肝脏组织具有保护作用。②100,200,300mg/kg白藜芦醇对肝脏组织发挥保护作用效果优于15,50mg/kg,建议使用100mg/kg白藜芦醇就能达到理想效果。 相似文献
62.
63.
64.
65.
66.
Background
Whole body vibration (WBV) exposure at work is common and studies found evidence that this exposure might cause low back pain (LBP). A recent review concluded there is a lack of evidence of effective strategies to reduce WBV exposure. Most research in this field is focussed on the technical implications, although changing behaviour towards WBV exposure might be promising as well. Therefore, we developed an intervention programme to reduce WBV exposure in a population of drivers with the emphasis on a change in behaviour of driver and employer. The hypothesis is that an effective reduction in WBV exposure, in time, will lead to a reduction in LBP as WBV exposure is a proxy for an increased risk of LBP. 相似文献67.
Bouma M Nuijen B Sava G Perbellini A Flaibani A van Steenbergen MJ Talsma H Kettenes-van den Bosch JJ Bult A Beijnen JH 《International journal of pharmaceutics》2002,248(1-2):247-259
This paper describes the development of a stable pharmaceutical dosage form for NAMI-A, a novel antimetastatic ruthenium complex, for Phase I testing. NAMI-A drug substance was characterized using several spectrometric and chromatographic techniques. In preformulation studies, it was found that NAMI-A in aqueous solution was not stable enough to allow sterilization by moist heat. The effect of several excipients on the stability of the formulation solution was investigated. None of them provided sufficient stability to allow long-term storage of an aqueous solution of NAMI-A. Therefore, a lyophilized product was developed. Five different formulations were prepared and subjected to thermogravimetric (TG) analysis and stability studies at various conditions for 1 year. Minimal degradation during the production process is achieved with a formulation solution of pH 3-4. Of the acids tested, only hydrochloric acid (HCl 0.1 mM) both stabilized the formulation solution and was compatible with the lyophilized product. This product was stable for at least 1 year when stored at -20 degrees C, 25 degrees C/60% relative humidity (RH) and 40 degrees C/75% RH, and was also photostable. 相似文献
68.
Kerbusch T Mathôt RA Otten HM Meesters EW van Kan HJ Schellens JH Beijnen JH 《Pharmacology & toxicology》2002,90(5):243-245
We report a case of a 39-year-old male with bipolar affective disorder who was admitted to hospital with an intentional acute lithium intoxication resulting in renal insufficiency. The patient had previously been treated with lithium, risperidone, fluoxetine and lorazepam, and successfully titrated to lithium levels of 0.7 mmol/l. After overdosing, the lithium level was 5.89 mmol/l and haemodialysis was initiated. A full pharmacokinetic time profile of lithium was obtained. After successful haemodialysis treatment, lithium levels recovered below toxic levels of 1.5 mmol/l in 53 hr. Without intervention non-toxic levels were not expected to have been reached within 6 days, based on computer simulation of predialysis levels. The patient was discharged 6 days after admission without residual symptoms. It was concluded that the lithium intoxication resulted from a combination of lithium overdose and subsequent renal insufficiency due to the overdose. A possible fluoxetine-risperidone interaction was not considered clinically apparent. 相似文献
69.
70.
Schoemaker NE van Kesteren C Rosing H Jansen S Swart M Lieverst J Fraier D Breda M Pellizzoni C Spinelli R Grazia Porro M Beijnen JH Schellens JH ten Bokkel Huinink WW 《British journal of cancer》2002,87(6):608-614
Polymeric drug conjugates are a new and experimental class of drug delivery systems with pharmacokinetic promises. The antineoplastic drug camptothecin was linked to a water-soluble polymeric backbone (MAG-CPT) and administrated as a 30 min infusion over 3 consecutive days every 4 weeks to patients with malignant solid tumours. The objectives of our study were to determine the maximal tolerated dose, the dose-limiting toxicities, and the plasma and urine pharmacokinetics of MAG-CPT, and to document anti-tumour activity. The starting dose was 17 mg m(-2) day(-1). Sixteen patients received 39 courses at seven dose levels. Maximal tolerated dose was at 68 mg m(-2) day(-1) and dose-limiting toxicities consisted of cumulative bladder toxicity. MAG-CPT and free camptothecin were accumulated during days 1-3 and considerable amounts of MAG-CPT could still be retrieved in plasma and urine after 4-5 weeks. The half-lives of bound and free camptothecin were equal indicating that the kinetics of free camptothecin were release rate dependent. In summary, the pharmacokinetics of camptothecin were dramatically changed, showing controlled prolonged exposure of camptothecin. Haematological toxicity was relatively mild, but serious bladder toxicity was encountered which is typical for camptothecin and was found dose limiting. 相似文献